

INTERIM REPORT

4th QUARTER & PRELIMINARY YEAR-END RESULTS 2021

All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1).

Currency neutral sales of own products increased by 38% for the quarter and 28% for the year.

Operating result (EBIT) for the quarter ended at MNOK 19.5 (MNOK 22.1). Operating result for 2021 ended at MNOK 116.3 (MNOK 95.5), a 21.8% increase. This is the best operating result for a year ever.

Cash flow from operations was a solid MNOK 127.5 for the year. Cash by the end of the year was MNOK 129.5.

Expert consensus paper published in the world-renowned journal Circulation with strong advocacy for the routine use of flow measurement technology.

The Board will suggest to the General Meeting a dividend of NOK 3.75 per share.

LETTER FROM THE CEO

It feels amazing to finish the year with another all-time high for quarterly sales;

with revenue of MNOK 112.7 and almost 20% growth in NOK. This is our fourth quarter in a row above 100 million NOK in revenues, and more important; the currency-neutral growth of own products is at 38%.

The EBIT ended at 17.3 % for the quarter and 27.6 % for the full year, taking both EBIT and pre-tax profit to a new annual high.

All geographical regions are doing well for the year, but 58 % currency-neutral growth from our largest sales region

USA really drives the quarterly performance to a new high.

The number of procedures sold in the USA, growing at 28 % for both the quarter and the year, not only indicates that the activity level in the surgical operating rooms is recouping the pent-up demand from the long COVID pandemic period, but that we have taken further market share as well. We estimate that our share of the total number of CABG procedures in the USA now lies above 25 %.

The continuous rebound from COVID has also resulted in a more normal quarter in terms of activity level and expenses. Marketing events and customer visits requiring travel, is picking up. Our most important annual conference, the International Coronary Conference (ICC) was arranged for the 7th time in New York as planned, with Medistim as one of the largest sponsors.

The quarter confirms continued positive development in our high-frequency ultrasound imaging product portfolio,

which is growing at 50 % in NOK for the quarter and 29 % for the full year. This indicates that we should be back at the pre-COVID growth momentum.

Also, the vascular business segment continues its positive path, with 54 % growth in NOK for the quarter and 21 % for the year.

Vascular sales revenues make up about 15 % of our growing total revenues from own products and look promising as a strong potential growth lever for us in the future.

While numbers are important and speak for themselves, unquestionably,

the most important news to report from the fourth quarter is the publication of an expert group consensus paper in the top medical journal Circulation.

Here, 19 world renowned cardiac surgeons have, on their own initiative, found it pressing to advocate for routine use of transit time flow measurement (TTFM) during every CABG surgery, performed by all cardiac surgeons – for the benefit of the patients' health and life expectancy. We believe this paper will contribute to cement the clinical value of the technology and accelerate change in clinical practice.

As we close another great year in Medistim's proud history, I take the opportunity to thank every Medistim colleague around the globe for their relentless efforts and stamina throughout the pandemic period, and for a spectacular 2021 result.



24th February 2022
Kari E. Krogstad
President and CEO

FOURTH QUARTER 2021 AND PRELIMINARY YEAR-END RESULTS

The financial report as per December 31st 2021 has been prepared according to the IFRS (International Financial Reporting Standard) and follows IAS 34 for interim financial reporting, as do the comparable numbers for 2020.

FINANCIAL DEVELOPMENT


(Comparative numbers for 2020 in parenthesis.)

Sales and geographic split

Sales revenues in the fourth quarter ended at MNOK 112.7 (MNOK 94.2), a 19.7% increase. There was growth in NOK in all regions except Europe. Sales in the USA was up 44.9%, while sales in Asia and "Rest of the World" were up 129.9% and 57.3%, respectively. Sales in Europe was down 11.7%.

Sales revenues for the full year ended at MNOK 427.3 (MNOK 363.1), a growth of 17.7%. There was growth in NOK of 21.9% in USA, while in Europe and Asia there was a growth of 9.8% and 42.7%, respectively. In "Rest of the World" there was a decline in sales of 3.0%

Total revenues for 2021 include an extraordinary recording of 5.3 MNOK as other revenues in the USA in the second quarter. This was related to the Paycheck Protection Program established by the U.S. federal government to help businesses keep employees employed during the COVID pandemic. Medistim has kept all its US employees throughout the pandemic and was therefore qualified for the program. Hence, U.S. product sales, when excluding this extraordinary income, increased with 17.7% for the full year.




Currency effect

With the same foreign currency exchange rates as in 2020, sales would have amounted to MNOK 119.4 for the quarter, which represents a currency-neutral total growth of 26.8%. Currency-neutral growth of own products was 38.4%, while third party products decreased by 13.4% compared to last year.

For 2021 there was a currency-neutral total growth of 24.6%. Currency-neutral growth of own products was 26.0% when excluding the debt forgiveness of 5.3 MNOK, while third party products increased with 10.0% compared to last year.

Split between recurring sales and capital sales

Sales of Medistim's own products can be split into capital sales of systems and repeating sales of probes, smartcards, and lease revenue, which are all defined as recurring revenue. In recent years, recurring sales were around 70% of total sales of own products. For 2021, the recurring sales represented 68.3%.



Split of sales in own products and third-party products

Sales of own products for the quarter amounted to MNOK 94.3 (MNOK 72.9). Sales of third-party products ended at MNOK 18.4 (MNOK 21.2).

Sales of own products in 2021 amounted to MNOK 347.6 (MNOK 295.6). Sales of third-party products ended at MNOK 74.3 (MNOK 67.51).

Split of sales in Cardiac and Vascular segment

For sales of own products, MNOK 77.0 (MNOK 61.7) was within the cardiac segment and MNOK 17.3 (MNOK 11.2) was within the vascular segment for the quarter.

For 2021, sales of own products within the cardiac segment was MNOK 293.0 (MNOK 250.5) and MNOK 54.6 (MNOK 45.1) was within the vascular segment. Hence, the vascular segment represents 15.7% (15.3%) of sales of own products in 2021.

Cost of goods sold

Cost of goods sold (COGS) ended at MNOK 27.9 for the quarter (MNOK 22.2) and represents 24.7% of total sales (23.6%). This gives a gross margin of 75,3% (76,4%).

Cost of goods sold (COGS) ended at MNOK 97.1 for 2021 (MNOK 76.6) and represents 22.7% of total revenues (21.1%). This gives a gross margin of 77,3% (78,9%).

The higher level of sales through distributors, product mix and increased sale of third-party products, explain the increase in COGS in percent of sales for both the quarter and 2021.

Salary, social and other operating expenses

Salaries and social expenses ended at MNOK 41.4 (MNOK 32.2) for the quarter. Other operating expenses amounted to MNOK 18.0 (MNOK 11.3) for the quarter.

Salaries and social expenses for the full year ended at MNOK 134.5 (MNOK 119.1). Other operating expenses amounted to MNOK 56.0 (MNOK 48.9) for 2021.

Strong sales results increase sales commissions and bonuses. Higher activity level also explains the increased expenses for the quarter and year. Expenses in 2020 was exceptionally low because of the COVID situation. For comparison, expense level in 2021 was 8 % above the expense level in 2019.

R&D expenses

For the quarter, MNOK 4.8 (MNOK 4.7) was spent on research and development (R&D), of which MNOK 1.4 (MNOK 1.2) was activated in the balance sheet.

The result before R&D, depreciation and write-offs was MNOK 28.9 (MNOK 31.9). This equals a margin of 25.6% (33.9%).


For 2021, MNOK 18.6 (MNOK 16.5) was spent on R&D, of which MNOK 4.1 (MNOK 1.9) was activated in the balance sheet.

The result before R&D, depreciation and write-offs was MNOK 154.2 (MNOK 133.1). This equals a margin of 36.0% (36.6%).

Earnings

Operating profit before finance, tax, depreciation and write-offs (EBITDA) for the quarter ended at MNOK 25.5 (MNOK 28.4). The result before finance and tax (EBIT) ended at MNOK 19.5 (MNOK 22.1).

For 2021, EBITDA ended at MNOK 139.7 (MNOK 118.6). The EBIT ended at MNOK 116.3 (MNOK 95.5), which is the best EBIT result ever.



Net finance ended negative with MNOK 0.046 for the quarter (negative MNOK 2.2). For 2021 net finance ended negative with MNOK 2.2 (negative MNOK 3.9). Net finance was related to realized and unrealized gains or losses related to currency, cash in USD and EUR, and customer receivables.

The result before tax was MNOK 19.4 (MNOK 19.9) for the quarter. The result after tax for the quarter was MNOK 16.1 (MNOK 13.9). For 2021, result before tax ended at MNOK 114.1 (MNOK 91.6). Result after tax ended at MNOK 90.9 MNOK (MNOK 69.4).

The result per share for the quarter was NOK 0.88 (NOK 0.75). The result per share year for 2021 was NOK 4.99 (NOK 3.81). Average number of shares outstanding was 18,215,932 (18,200,391) at the end of December 2021.

Balance sheet

Equity by the end of 2021 was MNOK 306.1 (MNOK 256.8). This equals an equity ratio of 75.9% (74.2%).

The balance sheet ended at MNOK 403.2 from MNOK 345.8 at the beginning of the year.

Inventory levels are still high securing end-of-life components and security stock of critical components. Still, the level is somewhat reduced due to longer lead times for some components.

Cash flow from operations at year end, ended at MNOK 127.9. The cash position at the end of December ended at MNOK 129.5. The company had no interest-bearing debt and MNOK 24.2 in obligations related to lease contracts was recognized in the balance sheet by year end according to IFRS 16.

OPERATIONAL STATUS

Europe

For the quarter, there was a decline in third-party sales with MNOK 2.8 as well as in sales of own products, decreasing with MNOK 3.6. Number of units sold was at the same level as last year, but there was more sales through distributors in 2021 compared to last year, where more of sales was through the direct channel. Currency neutral sales of own products was down 5.6%.

However, for the full year 2021, there was growth in both third-party sales and sales of own products. Third-party sales was up with MNOK 6.8 or 10.0 % while sales of own products was up MNOK 10.1 or 9.6 %. Currency neutral growth of own products in Europe was 15.7 %.

USA

Medistim offers several business models in the USA, including sales of procedures (Pay Per Procedure or 'PPP'), leasing, and capital sales.


For the quarter, sales revenues in NOK increased by 44.9 % to NOK 39.1. Currency neutral sales increased with 58.1%.

Similar for 2021, sales revenues increased in NOK by 17,7 % to MNOK 148,8 excluding the debt forgiveness. Currency neutral increase was 28.4%. The number of new customers in 2021 was 40 (25).

When including the 'Paycheck Protection Program' income of MNOK 5,3 from second quarter, the total revenue increase in 2021 was 21.9 % in NOK and 28.4% in USD.

For the quarter, a total of 17,821 procedures were sold, compared to last year's 13,899. 3,165 (1,935) were imaging procedures and 14,656 (11,964) flow procedures. Capital sales were 11 (3) units.

For 2021, a total of 72,032 procedures were sold, compared to last year's 56,059. 12,635 (8,803) were imaging procedures and 59,397 (47,256) flow procedures. Capital sales were 38 (26) units.



In the USA, about 70% of bypass surgeries are performed with no quality assurance of blood flow other than surgeons using their fingertips to check for a pulse. It is clinically proven that this method is not reliable.

There is therefore a large potential and need for Medistim's products, and the company has high ambitions in the U.S. market. So far, Medistim has achieved a market penetration of more than 25% of the total market of approximately 200,000 bypass surgery procedures performed annually. Medistim has a market penetration of about 80% in Germany, Scandinavia and Japan. Medistim expects that the market penetration in the USA will develop in the same manner over time.

Asia

Asia saw a 129.9% increase in sales for the quarter. For 2021 sales increased with 42.7% compared to last year. The sales increase was mainly driven by China and Japan, where both system sales and probe sales showed strong growth during 2021. Currency neutral sales was up 143% for the quarter and 50.7% for the year.

Rest of the World

Sales in 'Rest of the World' (MEA, Canada, South America and Australia) increased from MNOK 2.5 to MNOK 3.9 for the quarter and for 2021 sales declined from 16.7 MNOK to 16.1 MNOK. These markets constitute a relatively small sales region for Medistim so far, and are subject to considerable variation in sales from quarter to quarter. Currency neutral sales was up 66% for the quarter and 2.4% for the year.

CLINICAL UPDATE

Expert consensus paper advocating for routine use of TTFM

In the fourth quarter, Medistim's Transit Time Flow Measurement (TTFM) technology received strong support from leading experts, in a new publication in the top journal Circulation.

Circulation – the official journal of the American Heart Association – and one of the highest ranked journals in cardiology and cardiovascular medicine, published a consensus paper by 19 of the world's highest renowned specialists in coronary artery bypass surgery (CABG) on October 5th. The study describes a systematic review to identify best practice evidence for guideline development published the last 20 years. Over 2,200 articles identified, more than 1,550 of them screened, and 38 of them included in the review paper. The expert consensus process resulted in a new flowchart for decision making guidance to cardiac surgeons on how to utilize TTFM during surgery. The first of the 10 consensus statements and justifications states "TTFM should be used in every CABG case". The panelists agree "that quality assurance in CABG procedures should be established as a key component to improve patient outcomes".

This is a pivotal paper for Medistim that clearly graces all the initiatives to position the MiraQ technology for routine use during CABG surgery. Having the technology in focus in one of the world's most renowned cardiovascular journals indicate that Medistim is moving in the right direction with its strategy. Medistim's REQUEST study published in 2020 was one of the key papers that was assessed to underpin the importance of routine use of quality assessment. This strong advocacy will not only exert peer influence within the community of cardiac surgeons, but it may pave the way for new and enhanced clinical guidelines worldwide.

PROSPECTS AND TRENDS

Goals and vision

The company aims to develop products to meet surgeons' growing need for quality control of cardiac bypass surgery, peripheral vascular surgery, and transplant surgery. Our vision is that Medistim's solutions shall represent the "standard of care" in clinical practice and that blood flow measurements and intraoperative ultrasound imaging are made available to the benefit of every patient.

Strategy

Medistim's focus is to strengthen the company's ability to effectively commercialize its product portfolio on a global basis. One of the key routes to achieve this is closer contact with customers through a highly competent and effective sales and marketing organization. Another important strategic pathway is to engage with key opinion leaders in clinical research and produce enhanced clinical documentation for marketing purposes. Further, to grow the attention and interest in blood flow measurements, ultrasound imaging, surgical guidance and quality assurance and ensure these topics are on the agenda of the medical associations and in other relevant forums and channels.

Continuous technology and product development will secure Medistim's products and leading position within cardiac and vascular surgery in the future.

Market size and trends

On a global basis, more than 700,000 heart bypass surgeries are performed each year. The USA represents the largest market for Medistim's products, with almost 1/3 of the world market. The global number of procedures has kept stable over the past several years. The decrease in the number of procedures performed in the Western countries has been compensated by an increase in emerging markets such as China, Russia, and India. A stable to growing trend is therefore expected in the years to come.

Adding intraoperative ultrasound imaging to flow measurements more than doubles Medistim's market potential thanks to new applications and relevance and higher pricing compared to traditional flow measurement technology alone.

The total market opportunity within CABG surgery is estimated to be NOK 2 billion annually. The imaging functionality makes MiraQ™ relevant in other cardiac surgeries and not just bypass surgery. Medistim estimates this additional potential to be NOK 1 billion.

The company also has a significant potential within the global vascular market, which is estimated to be more than 900,000 vascular procedures annually. Total market opportunity within vascular surgery is estimated to be over NOK 1.5 billion.

The general trend in surgery is moving towards minimally invasive and keyhole procedures, which gives the surgeon less workspace and ability to verify in a traditional way. There is therefore an increased need to verify the desired result in the future.

Global demographic trends are an important driving force for the many cost-efficiency initiatives around the world. Focus on quality is growing, driven by the need to reduce costs, particularly related to correction of errors, the need for repeated treatments and repeated hospital admissions. Medistim therefore has a good opportunity to position its products as an important contributor to achieving these goals.

Position and Competition

Medistim's flowmeters have been in use in more than two million patients worldwide since entering the market, and the company is the clear leader in its niche. In total, Medistim has installed 3,150 systems in more than 65 countries. The equipment is used today in about 33% of the total number of bypass surgeries performed worldwide. Medistim's penetration and market share are expected to grow gradually as quality assurance in surgery is getting increasing attention and acceptance.

There are competitors that use the transit time measurement principle. Equipment from competitors is estimated to be in use in about 7% of the procedures performed. This means that in about 60% of the cases where bypass surgery is performed there is no equipment in use to verify blood flow. This market represents Medistim's largest opportunity.

With Medistim's ultrasound imaging technology and MiraQ™ platform, the company has acquired another edge compared to its competitors, with unique and differentiated products that are currently alone in their segment.

Exposure towards currency

The company is exposed to EUR and USD. Exposure can vary depending on the share of its revenues and costs in USD and EUR relative to its total income and expenses. For 2021, a 10% change in the exchange rate against USD and EUR would result in an 8.2% change in sales and a 13.0% change in operating result. The company partly secures its positions with hedging contracts.

The COVID-19 pandemic

Cardiac bypass surgery is to a large extent an elective procedure that can be scheduled with some time delay. When the outbreak of the COVID pandemic was a fact, several bypass surgeries were postponed. Therefore, the number of by-pass procedures was reduced compared to the normal level. While Medistim has over several years shown a currency neutral growth of 7% to 10 % per year, 2020 ended without growth compared to 2019, all due to the pandemic.

Since the pandemic started to affect the Medistim business in second quarter of 2020, the effect has become gradually smaller, and in the second quarter of 2021, there was a strong rebound in procedures performed and hence in the sales revenues. This rebound continues in this fourth quarter of 2021 and we continue to experience strong growth in revenues due to the increase in number of CABG procedures performed. This increase corresponds with the reduction in hospitalizations of patients with COVID disease, which is again an effect of the growing vaccination rates in Medistim's core markets, Europe, and USA, and to some degree also in Japan and China.

Due to lower operating costs from traveling, conferences, general cost containment and sales growth, Medistim reports an all-time high EBIT result for 2021. Cash flow from operation was a solid MNOK 127.6 and the cash position was MNOK 129.5 by year end.

While Medistim has been affected by the COVID situation, the company has been able to deliver solid profit and cash flow. The need for Medistim's products has not changed, and the strong recovery seen through 2021 may indicate that cardiac bypass surgeries are at large back to normal. However, there are still some uncertainties related to new variants of the virus.


SHAREHOLDER INFORMATION

The company had 108,422 Medistim shares by the end of December 2021. The shares were purchased at a price per share of NOK 14.70. The share price was NOK 367.50 per share at the end of 2021. For comparison, entering 2021 the share price was 250.00 per share.

The number of shares sold in the fourth quarter of 2021 totaled 4,611,323. The five largest

shareholders were Aeternum Capital with 1,862,500 shares, Odin Fondene with 1,800,000 shares, Fløtemarken AS with 1,285,000 shares, State Street Bank with 1,240,079 shares and State Street Bank with 1,117,246 shares.

The Board will suggest to the General meeting a dividend of NOK 3.75 per share based upon the 2021 results.



Oslo February 24th 2021

Board of Directors and CEO of Medistim ASA

Øyvind A. Brøymer
Chairman
Sign.

Siri Fürst
Board member
Sign.

Torben Jørgensen
Board member
Sign.

Tove Raanes
Board member
Sign.

Lars Rønn
Board member
Sign.

Kari Eian Krogstad
CEO
Sign.

PROFIT & LOSS	Q4 2021	Q4 2020	FY 2021	FY 2020
1=NOK 1000				
Sales revenue	112 740	94 184	421 984	363 133
Other revenue	-	-	5 292	-
Total revenue	112 740	94 184	427 276	363 133
Cost of goods sold	27 884	22 232	97 114	76 577
Salary and social expenses	41 418	32 177	134 507	119 066
Other operating expenses	17 951	11 348	55 950	48 865
Total operating expenses	87 252	65 756	287 571	244 508
Op. res. before depr. and write-offs (EBITDA)	25 488	28 429	139 705	118 626
EBITDA%	22.6%	30.2%	33.1%	32.7%
Depreciation	6 027	6 293	23 427	23 141
Operating profit (EBIT)	19 461	22 136	116 278	95 484
EBIT %	17.3%	23.5%	27.2%	26.3%
Financial income	1 664	1 433	8 173	14 137
Financial expenses	1 710	3 648	10 380	18 015
Net finance	(46)	(2 216)	(2 207)	(3 878)
Pre tax profit	19 415	19 920	114 071	91 606
Tax	3 302	6 352	23 171	22 219
Profit after tax	16 113	13 568	90 900	69 387
Dividend	-	-	54 640	50 052
Comprehensive income				
Profit after tax	16 113	13 568	90 900	69 387
Exchange differences arising on translation of foreign operations	686	(6 490)	5 357	(965)
Total comprehensive income	16 799	7 078	96 257	68 422
KEY FIGURES	Q4 2021	Q4 2020	FY 2021	FY 2020
1 = NOK 1000				
Equity share	75.90%	74.27%	75.90%	74.27%
Earnings per share	NOK 0.88	NOK 0.75	NOK 4.99	NOK 3.81
Earnings per share diluted	NOK 0.88	NOK 0.74	NOK 4.98	NOK 3.80
Average shares outstanding in 1000	18 224	18 200	18 216	18 200
Average shares outstanding in 1000 diluted	18 257	18 237	18 249	18 237

SPLIT OF EBIT PER SEGMENT	Q4 2021	Q4 2020	FY 2021	FY 2020
1 =NOK 1000				
EBIT from Medistim products	17 208	18 410	102 741	86 334
EBIT margin Medistim products	18.2 %	25.2 %	29.6 %	29.2 %
EBIT from 3 rd party products	2 252	3 726	13 537	9 150
EBIT margin 3 rd party products	12.2 %	17.5 %	18.2 %	13.5 %
Total EBIT	19 461	22 136	116 278	95 484
Total EBIT margin %	17.3%	23.5%	27.2%	26.3%

BALANCE SHEET	12/31/2021	12/31/2020
1=NOK1000		
Assets		
Intangible assets	33 410	33 463
Fixed assets	63 337	66 570
Total intangible and fixed assets	96 747	100 033
Inventory	97 413	112 667
Customers receivables	68 634	57 485
Other receivables	10 960	3 744
Cash	129 490	71 891
Total current assets	306 497	245 787
TOTAL ASSETS	403 244	345 820
Equity and liability		
Share capital	4 585	4 585
Share premium reserve	44 172	44 172
Other equity	257 295	208 089
Total equity	306 052	256 846
Lease obligations	17 079	21 652
Deferred income	2 510	265
Other long term debt	-	7 580
Total long term debt	19 589	29 497
Total short term debt	77 603	59 477
TOTAL EQUITY AND LIABILITY	403 244	345 820

CHANGE IN EQUITY	12/31/2021	12/31/2020
1 =NOK 1000		
Equity start of period	256 846	236 861
Result for the period	90 900	69 387
Dividend	(54 640)	(50 052)
Medistim shares	7 589	1 615
Changes in exchange rates	5 357	(965)
Equity end of period	306 052	256 846

CASH FLOW ANALYSIS	12/31/2021	12/31/2020
1=NOK1000		
Result for the period	90 900	69 387
Other cash flow from operation	37 019	4 946
Cash flow from operation	127 919	74 333
Cash flow from investments	(11 486)	(10 639)
Cash flow from financial activities	(58 834)	(58 549)
Change in cash for the period	57 599	5 145
Cash at the start of period	71 891	66 745
Cash by the end of period	129 490	71 891

GEOGRAPHIC SPLIT OF SALES	Q4 2021	Q4 2020	FY 2021	FY 2020
1=NOK1000				
USA	39 092	26 974	154 135	126 408
Asia	20 331	8 844	66 805	46 811
Europe	49 346	55 841	190 190	173 263
Rest of the World	3 972	2 525	16 146	16 651
TOTAL REVENUE	112 740	94 184	427 276	363 133

SPLIT OF SALES PER PRODUCT SEGMENT	Q4 2021	Q4 2020	FY 2021	FY 2020
1=NOK 1000				
USA				
Procedural revenue flow	20 554	17 870	81 974	75 484
Procedural revenue Imaging and flow	8 023	5 489	29 780	23 892
Capital sale flow systems	5 573	2 796	18 108	12 022
Capital sales imaging and flow systems	4 945	819	18 984	15 011
Outside USA				
Flow systems	11 981	10 683	32 898	35 225
Imaging and flow systems	10 151	9 149	38 912	29 179
Imaging probes	2 031	1 291	7 118	5 219
Flow probes	30 324	22 831	115 704	92 626
Other	761	2 016	4 169	6 927
Total sale of Medistim products	94 343	72 944	347 646	295 585
Other USA	(2)	-	5 290	
Sale of 3 rd party products	18 399	21 240	74 340	67 549
TOTAL REVENUE	112 740	94 184	427 276	363 134
SPLIT OF SALES BETWEEN CARDIAC AND VASCULAR SURGERY	Q4 2021	Q4 2020	FY 2021	FY 2020
1=NOK 1000				
Sales within coronary surgery	77 002	61 703	293 025	250 483
Sales within vascular surgery	17 339	11 241	54 619	45 102
Other	-	-	5 292	
Sales of 3 rd party products	18 399	21 240	74 340	67 549
TOTAL REVENUE	112 740	94 184	427 276	363 134

GEOGRAPHIC SPLIT OF SALES IN UNITS	Q4 2021	Q4 2020	FY 2021	FY 2020
USA				
Procedures flow measurements	14 656	11 964	59 397	47 256
Procedures imaging and flow	3 165	1 935	12 635	8 803
Capital sales flow systems	7	2	22	14
Capital sales imaging and flow systems	4	1	16	12
Lease flow systems	3	3	9	10
Lease imaging and flow systems	2	3	10	3
Asia				
Flow systems	16	9	59	63
Imaging and flow systems	12	3	34	19
Imaging probes	18	1	46	26
Flow probes	783	463	2 683	1 693
Europe				
Flow systems	23	22	54	52
Imaging and flow systems	6	9	27	19
Imaging probes	17	16	50	36
Flow probes	1 214	1 167	4 524	3 943
Rest of the world				
Flow systems	3	(1)	12	9
Imaging and flow systems	1	1	6	9
Imaging probes	4	5	11	13
Flow probes	264	138	781	582
Total sales outside the US in units				
Flow systems	42	30	125	124
Imaging and flow systems	19	13	67	47
Imaging probes	39	22	107	75
Flow probes	2 261	1 768	7 988	6 218

marketing@medistim.com
www.medistim.com

Medistim ASA (Head office)
Økernveien 94
0579 Oslo
Norway
Phone +47 23 05 96 60

Medistim ASA (Manufacturing)
Bromsveien 17
3183 Horten
Norway
Phone +47 33 03 17 26

Medistim Norge AS
Økernveien 94
0579 Oslo
Norway
Phone +47 23 03 52 50

Medistim Danmark ApS
Søgade 16
4100 Ringsted
Denmark
Phone +45 23 800 300

Medistim USA Inc.
14000 25th Ave N. Ste. 108
Plymouth, MN 55447
USA
Phone +1 763 208 9852

Medistim Deutschland GmbH
Bahnhofstr. 32
82041 Deisenhofen
Germany
Phone +49 (0) 89 62 81 90 33

Medistim Spain S.L.
Calle Balmes 173, 4º, 2
08006 Barcelona,
Spain
Phone +34 911 238 318

Medistim UK Limited
34 Nottingham South Ind Est
Ruddington Lane Wilford
NG11 7EP Nottingham, UK
Phone +44 (0) 115 981 0871